BridgeMD
An open non-randomized phase IV trial examining interfering cross-reactivity in serological diagnostics of flavivirus infections in Swedish travelers following vaccination with the live dengue vaccine Qdenga
EU CTIS ID: 2025-520655-92-00
What this study is testing
To assess whether the Qdenga vaccine cause significantly elevated levels of cross-reactive IgG antibody levels against TBEV, YFV, ZIKV and JE at day 90 after two doses of Qdenga compared to before vaccination.
- Therapeutic use (Phase IV)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Able to participate in all parts of the study
- Signed written informed consent
- 18 years of age or older
- Negative pregnancy test (urine HCG) for women of childbearing potential
- Planning to travel to a dengue fever endemic country. The guidelines by the Swedish Society for Infectious Diseases Physicians will be used in a shared decision-making process when deciding on vaccination
You likely can't join if
- Unable to provide signed written informed consent
- Cancer diagnosis with active treatment (excluding hormone treatment only)
- Allergy to a component of the Qdenga® vaccine
- Not suitable for participation in the study according to the view of the investigator
- Participation or recent participation (within 30 days from inclusion) in a clinical trial with an investigational medicinal product
- Previous participation in this trial
See the full eligibility criteria
- Able to participate in all parts of the study
- Signed written informed consent
- 18 years of age or older
- Negative pregnancy test (urine HCG) for women of childbearing potential
- Planning to travel to a dengue fever endemic country. The guidelines by the Swedish Society for Infectious Diseases Physicians will be used in a shared decision-making process when deciding on vaccination
- Unable to provide signed written informed consent
- Cancer diagnosis with active treatment (excluding hormone treatment only)
- Allergy to a component of the Qdenga® vaccine
- Not suitable for participation in the study according to the view of the investigator
- Participation or recent participation (within 30 days from inclusion) in a clinical trial with an investigational medicinal product
- Previous participation in this trial
- Previous vaccination with a dengue fever vaccine
- Pregnancy or breastfeeding
- Immunocompromised condition due to illness or medication which prevents vaccination with a live vaccine according to the view of the investigator
- Systemic cortisone treatment (inhaled corticosteroids are allowed)
- Previous or present hepatitis B, hepatitis C and/or HIV
- Chronic liver failure (Child-Pugh Class B or higher)
- Chronic kidney disease (CKD stage 3 or higher)
- Autoinflammatory disease (i.e. inflammatory bowel disease, rheumatological disease or dermatological disease)
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18-64 years, 65+ years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.